Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2012
03/14/2012CN102370645A Anticancer drug composition
03/14/2012CN102370634A Application of epigallocatechin gallate
03/14/2012CN102370632A Application of SIRT1 micro-molecular inhibitor in preparation of medicines for treating or preventing caner and protein deacetylation related diseases
03/14/2012CN102370622A Medicament carrying nano particles and preparation method and application thereof
03/14/2012CN102370618A Emulsion containing Temodal, preparation technology thereof and purpose thereof
03/14/2012CN102370395A Chinese medicinal health-care pillow and manufacturing method thereof
03/14/2012CN102370163A Novel biological material, preparation method and application thereof
03/14/2012CN102127119B Preparation method of miboplatin
03/14/2012CN101984997B Anti-tumor composition containing four-substance decoction extract and application thereof
03/14/2012CN101961476B Anti-tumor traditional Chinese medicine and preparation method thereof
03/14/2012CN101835495B Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases
03/14/2012CN101773480B Preparation method of Nnanocrystal preparation containing docetaxelDuoxitasai and method for preparing a freeze-drying agent thereof
03/14/2012CN101757128B Extraction and preparation method of total phenol of compound abnormal savda munziq
03/14/2012CN101627983B Medicinal composition for inhibiting angiogenesis and application thereof
03/14/2012CN101564388B Composition for Danshensu and danshinolic acid B and use thereof
03/14/2012CN101528925B Dbait and uses thereof
03/14/2012CN101519655B Abalone HINT gene and protein and application of same for preparing anticarcinogenic drug
03/14/2012CN101444538B Application of Escherichia coli and gene engineering bacteria thereof in preparing anti-liver-cancer solid tumor drugs
03/14/2012CN101384264B Therapeutic combinations comprising poly (adp-ribose) polymerases inhibitor
03/14/2012CN101360495B Administration of mntor inhibitor to treat patients with cancer
03/14/2012CN101318011B Pentapeptide nose spraying agent for thymus gland, preparation method and application thereof
03/14/2012CN101284008B IL-4R antagonist and microorganism for generating the IL-4R antagonist
03/14/2012CN101233225B Strain of turkey tail mushroom, extract from the same, and use of the same
03/14/2012CN101148467B Oligonucleotide and use thereof for treating lung cancer
03/14/2012CN101096359B Polyaryl substituted methane oxygen or silica radical guanidine compound and preparation method and usage thereof
03/14/2012CN101090710B Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
03/13/2012US8133995 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
03/13/2012US8133983 Agonistic binding molecules to the human OX40 receptor
03/13/2012US8133889 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
03/13/2012US8133877 Composition comprising an antisense sequence implicated in the regulation of angiogenesis
03/13/2012US8133873 Recombinant chemokine-antigen vaccine
03/13/2012CA2565812C 4-phenylamino-quinazolin-6-yl-amides
03/13/2012CA2513144C Phospholipid derivative and method for producing the same
03/13/2012CA2489227C Hla-a24-restricted cancer antigen peptides
03/13/2012CA2480468C Fredericamycin derivatives
03/13/2012CA2442854C Hsa-free formulations of interferon-beta
03/13/2012CA2407238C The use of thymosin alpha 1 to reduce the side effects of chemotherapy in cancer patients
03/13/2012CA2369074C Ether compounds, compositions, and uses thereof
03/13/2012CA2361806C Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
03/13/2012CA2347649C Mn gene and protein
03/13/2012CA2256308C Antibodies to the ed-b domain of fibronectin, their construction and uses
03/08/2012WO2012031296A2 Methods and composition for inhibiting or attenuating leukocyte-endothelial interactions
03/08/2012WO2012031205A2 Lipid-polymer hybrid particles
03/08/2012WO2012031199A1 Guanidine compounds and compositions for the inhibition of nampt
03/08/2012WO2012031197A1 Novel compounds and compositions for the inhibition of nampt
03/08/2012WO2012031196A1 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
03/08/2012WO2012031175A2 Nanoparticle-based tumor-targeted drug delivery
03/08/2012WO2012031137A2 Vesicular stomatitis viruses
03/08/2012WO2012031118A2 Cell permeable inhibitors of anaphase promoting complex
03/08/2012WO2012031103A2 Inhibitors of bcl-2
03/08/2012WO2012031004A1 Pyridinones/pyrazinones, method of making, and method of use thereof
03/08/2012WO2012030990A1 Pyridazinones, method of making, and method of use thereof
03/08/2012WO2012030948A1 Quinazoline compounds and methods of use thereof
03/08/2012WO2012030944A2 Quinoline and isoquinoline compounds and methods of use thereof
03/08/2012WO2012030924A1 Azolopyridine and azolopyrimidine compounds and methods of use thereof
03/08/2012WO2012030917A1 An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
03/08/2012WO2012030914A1 4-azolylaminoquinazoline derivatives and methods of use thereof
03/08/2012WO2012030913A1 An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
03/08/2012WO2012030912A1 7-cyclylquinazoline derivatives and methods of use thereof
03/08/2012WO2012030910A1 2-cycloquinazoline derivatives and methods of use thereof
03/08/2012WO2012030896A2 Methods for treatment of non-small cell lung cancer
03/08/2012WO2012030894A1 Thienopyridine and thienopyrimidine compounds and methods of use thereof
03/08/2012WO2012030886A1 Combination of hdac inhibitors with thrombocytopenia drugs
03/08/2012WO2012030885A1 Hydrobromide salts of a pyrazolylaminoquinazoline
03/08/2012WO2012030854A2 Compositions and methods for modulating emt and uses thereof
03/08/2012WO2012030234A1 Methods and compositions for treating cancer
03/08/2012WO2012030160A2 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
03/08/2012WO2012030152A2 Composition for preventing and treating prostate cancer including alpinia katsumadai hayata extract
03/08/2012WO2012030150A2 Composition for preventing and treating prostate cancer containing ailanthus altissima swingle organic solvent extract
03/08/2012WO2012030149A2 Composition for preventing and treating prostate cancer containing caesalpinia sappan l. extract
03/08/2012WO2012030148A2 Composition for preventing and treating prostate cancer including thistle root extract
03/08/2012WO2012030147A2 Composition for treating prostate cancer including tussilago farfara linne extract
03/08/2012WO2012030142A2 Composition for treating prostate cancer including spikenard extract
03/08/2012WO2012029954A1 Process for production of novel degalactosylated gc globulin
03/08/2012WO2012029827A1 Process for producing drug—block-copolymer composite and pharmaceutical product containing same
03/08/2012WO2012029771A1 Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation using tumor proliferation inhibitor and low-intensity pulsed ultrasound
03/08/2012WO2012029609A1 Compound having silicon-containing substituent introduced thereto, and singlet oxygen-generating agent and cancer therapeutic comprising same
03/08/2012WO2012029456A1 Oil-in-water emulsion composition containing poorly-soluble drug, and method for manufacturing same
03/08/2012WO2012029326A1 3-pyrazolyl-2-pyridone derivative
03/08/2012WO2012029023A1 Antibodies that bind to adrenomedullin and to adrenomedullin receptors and the uses thereof as drugs
03/08/2012WO2012028861A1 Pure erlotinib
03/08/2012WO2012028758A1 Use of crassula for treating proliferative diseases
03/08/2012WO2012028332A1 Pharmaceutically active compounds as axl inhibitors
03/08/2012WO2012028311A1 Compositions comprising a taxane for coating medical devices
03/08/2012WO2012028243A1 Pyrazolopyridinone derivatives as lpa receptor antagonists
03/08/2012WO2012028233A1 Imidazo[4,5-c]quinolines as dna-pk inhibitors
03/08/2012WO2012028106A1 Deuterium-enriched heterocyclic compounds as kinase inhibitors
03/08/2012WO2012027957A1 Bufalin derivatives, pharmaceutical compositions and use thereof
03/08/2012WO2012012300A3 Treatment of the adverse side-effects associated with administration of an anti-hyaluronan agent
03/08/2012WO2012010675A3 Bhlh proteins and their use as drugs
03/08/2012WO2012003912A8 Bipyridyl derivatives useful for the treatment of kinase - induced diseases
03/08/2012WO2012001149A3 Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
03/08/2012WO2011153226A3 Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
03/08/2012WO2011143160A9 Metabolic inhibitor against tumors having an idh mutation
03/08/2012WO2011140334A3 Compounds, methods of making or identifying compounds, and uses thereof
03/08/2012WO2011136911A3 Anti-erbb3 antibodies
03/08/2012WO2011133875A3 Metalloenzyme inhibitor compounds
03/08/2012WO2011133819A3 Methods of enhancing antibody-dependent cellular cytotoxicity
03/08/2012WO2011133475A3 Compositions and method for the treatment of multiple myeloma
03/08/2012WO2011132967A3 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same
1 ... 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 ... 2211